Workflow
GZBL(002424)
icon
Search documents
苗药龙头贵州百灵再遭ST:三年虚增6.5亿利润,董事长被罚500万并禁入市场10年
Sou Hu Cai Jing· 2025-12-23 01:48
图源:文轩图库 半年时间,两度被戴帽,上市十余年之久的贵州百灵,这一次因虚增6个亿被罚,再度失信于股民。 公开信息显示,贵州百灵企业集团制药股份有限公司(以下简称:贵州百灵)前身为1999年成立的贵州省安顺地区制药厂,是一家以苗药研发、生产、销 售于一体的医药公司。 2010年,成功登陆深交所,被称为"中国苗药第一股",目前已发展成为国内最大的苗药研制生产企业。 巅峰期的贵州百灵在资本市场的市值一度达到531亿,然而,截至目前市值仅为78.68亿元,跌幅超过85%。 半年内摘帽又戴帽 伤透股民的心 12月19日晚间,实现连涨3天的贵州百灵突然发布公告称,公司及相关当事人已收到贵州证监局送达的《行政处罚事先告知书》。经查,公司在2019年至 2023年期间存在财务造假行为,具体表现为: 2019年少计销售费用3.5亿元,相应多计利润3.5亿元,占当期报告记载利润总额(绝对值)的95.73%;2020年少计销售费用2.4亿元,多计利润2.4亿元, 占比达115.35%;2021年少计销售费用6379.16万元,多计利润6379.16万元,占比45.04%;2023年则多计销售费用4.59亿元,少计利润4.59亿元 ...
贵州百灵(002424)被罚1000万!4年财务造假,两类投资者可索赔
Xin Lang Cai Jing· 2025-12-23 01:17
登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权:http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们! 2025年12月20日,贵州百灵企业集团制药股份有限公司(以下简称"贵州百灵"或"公司")发布公告称, 公司及相关责任人收到贵州证监局下发的《行政处罚事先告知书》(黔处罚字[2025]1号-11号)。据处 罚内容,其因2019-2021年虚增利润及2023年虚减利润致四年年报虚假记载,公司被警告并罚款1000万 元,11名相关责任人合计罚款1560万元,公司股票被实施其他风险警示,不触及重大违法强制退市。上 海市信本律师事务所赵敬国律师(执业证号:13101200410820485)提示,(1)于2024年1月31日-2024 年4月29日期间买入且有持仓,无论在2024年4月30日及之后是否卖出;(2)于2020年4月30日-2024年4 月29日期间买入且有持仓,无论在2024年4月30日及之后是否卖出的受损投资者,或可通过"新浪股民维 权平台 ...
“苗药第一股”翻车:贵州百灵四年造假6.5亿,昔日贵州首富被禁入市场十年
Guan Cha Zhe Wang· 2025-12-22 15:10
登录新浪财经APP 搜索【信披】查看更多考评等级 具体而言,公司未遵循收入与成本费用配比的原则,在财务核算中未能将实际发生的销售费用在当期及 时、足额确认。简单来说,就是通过故意推迟确认、或少计与当期收入相关的市场推广、渠道维护等销 售费用,将这些本应立刻体现在利润表中的支出"隐藏"或"转移",从而人为做高当期利润。 【文/王力 编辑/周远方】 12月19日晚间,一则来自贵州证监局的《行政处罚事先告知书》,揭开了这家曾被誉为"苗药第一股"的 上市药企长达四年的财务造假真相。贵州百灵(002424.SZ)因在2019年至2021年及2023年年报中存在 虚假记载,被监管机构处以1000万元顶格罚款,公司股票将被实施其他风险警示,简称由"贵州百灵"变 更为"ST百灵(维权)"。 这家以银丹心脑通软胶囊、咳速停糖浆等产品闻名的苗药龙头,曾在2017年将其实际控制人姜伟家族推 上贵州首富的宝座,巅峰时期身家高达165亿元。如今,姜伟不仅面临500万元顶格罚款,还将被采取10 年证券市场禁入措施。与此同时,包括总经理牛民在内的10名责任人被处以合计1560万元罚款。 经查实,贵州百灵通过不当核算销售费用的方式,在201 ...
贵州百灵财务造假被重罚,与纾困方华创证券矛盾日益激化
Da Zhong Ri Bao· 2025-12-22 09:31
12月20日,贵州百灵(002424.SZ)披露《行政处罚告知书》,因2019年至2023年间持续财务造假,公 司及相关责任人遭贵州监管局重罚。 四年调控利润11.14亿元,被罚2560万元 根据处罚决定,贵州百灵被处以1000万元罚款;实控人、董事长姜伟罚款500万元并被采取10年证券市 场禁入措施;时任董事、总经理、董秘牛民,时任董事、副总经理姜勇分别被罚350万元、200万元;另 有封基贤等7名相关责任人分别被处以50万至150万元不等罚款,合计罚没金额达2560万元。 《经济参考报》在此前报道中也统计,贵州百灵在2021年5—6月、2022年3月及12月曾出现多笔不合常 理的股价异动。公司副总经理陈培怀疑,华创证券涉嫌通过"融券做空"操纵股价,而股价下跌直接导致 大股东姜伟需不断补充质押物,自身利益受损。不过上述举报均未获得监管部门的违规认定。 截至2025年三季度末,华创证券旗下两只纾困基金仍持有贵州百灵11.54%的股份,为公司第二大股 东,双方的诉讼纠纷尚未有明确结果。 纾困变博弈:与华创证券股权纠纷愈演愈烈 就在财务造假处罚落地之际,贵州百灵与华创证券之间持续数年的矛盾进一步浮出水面。这场纠纷 ...
贵州百灵(002424)收到处罚事先告知书,部分时段索赔已有胜诉
Xin Lang Cai Jing· 2025-12-22 07:31
受损股民可至新浪股民维权平台登记该公司维权:http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们! 2025年12月20日,贵州百灵(维权)(002424)公告收到证监会下发的《行政处罚事先告知书》,上海 久诚律师事务所股票索赔律师许峰提示,贵州百灵涉嫌的虚假陈述违法事实已基本清楚,如果投资者因 此受损,目前还可发起索赔,部分时段投资者已有胜诉先例。(许峰律师专栏) 许峰律师代理的贵州百灵投资者索赔案已向法院提交立案,目前正在等待法院的下一步安排,律师团队 还在继续推进后续案件的立案工作,还在继续接受后续投资者的索赔委托。 上述《行政处罚事先告知书》公告信息显示,经查,贵州百灵涉嫌违法的事实如下: 贵州百灵在财务核算时未执行《企业会计准则—基本准则》第九 条的规定,未以权责发生制为核算基 础,按收入成本费用配比原则计 提销售费用。贵州百灵 2019 年少计销售费用 35,012.49 万元,多计 利润 35,012.49 万元,占当期报告记载利润总额(绝对值)的 95.73%;2020 年少计销 ...
“苗药第一股”贵州百灵因财务造假“戴帽”,受损投资者可积极参与索赔
Xin Lang Cai Jing· 2025-12-22 07:31
受损股民可至新浪股民维权平台登记该公司维权:http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们! 一、两类投资者可索赔 贵州证监局在12月19日发布了对贵州百灵(维权)的行政处罚事先告知书,公司多年财务造假行为被曝 光。公司在2019年至2021年期间累计虚增利润达6.55亿元,2023年又虚减利润4.59亿元。 根据《深圳证券交易所股票上市规则》,上市公司因财务指标虚假记载将被实施其他风险警示。贵州百 灵集团总部的企业标识旁,再次贴上了"ST"的警示标签,距离它上次摘掉这个标签仅过去不到半年。 上海沪紫律师事务所刘鹏律师团队已收到数百位投资者的索赔报名,此次预处罚的送达也为后续诉讼提 供了有力的征集支持。(刘鹏律师专栏) 现针对其索赔条件进行了改动,目前符合以下任意区间的即可登记索赔:(ST百灵维权入口) (本文由上海沪紫律师事务所刘鹏律师供稿,不代表新浪财经的观点。刘鹏律师,专注证券维权19年, 自2006年执业以来,成功为中青宝、国华网安、劲嘉股份(维权)等 300 余家上市公司的中小投 ...
贵州百灵被预处罚,股民索赔可期
Xin Lang Cai Jing· 2025-12-22 06:08
Core Viewpoint - Guizhou Bailing Pharmaceutical Group Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for financial misconduct, including underreporting sales expenses and overstating profits in multiple fiscal years [2][3]. Financial Misconduct Summary - Guizhou Bailing failed to adhere to the accounting standards, resulting in the following discrepancies: - In 2019, sales expenses were understated by 350.12 million yuan, leading to an overstatement of profits by the same amount, which constituted 95.73% of the reported profit for that year [2]. - In 2020, the company understated sales expenses by 240.81 million yuan, resulting in a profit overstatement of 240.81 million yuan, which was 115.35% of the reported profit [2]. - In 2021, sales expenses were understated by 63.79 million yuan, leading to a profit overstatement of 63.79 million yuan, accounting for 45.04% of the reported profit [2]. - In 2023, sales expenses were overstated by 459.41 million yuan, resulting in an understatement of profits by the same amount, which was 93.17% of the reported profit [2]. Legal and Regulatory Actions - The CSRC plans to impose penalties on Guizhou Bailing, its actual controller Jiang Wei, and other responsible personnel, including warnings and fines [2]. - Investors affected by the company's financial misstatements may seek civil compensation for losses incurred due to the misleading information [3]. - A lawyer from Shanghai Hanlian Law Firm is actively recruiting investors who purchased Guizhou Bailing's securities before April 30, 2024, to assist in filing compensation claims [3][4]. Investor Compensation Process - Investors can register for compensation if they bought Guizhou Bailing's stocks or bonds before April 30, 2024, and sold or held them afterward [3]. - Required materials for compensation registration include a copy of the ID, original securities account confirmation, and original transaction records [4].
贵州百灵财务造假案处罚方案出炉
Jing Ji Guan Cha Wang· 2025-12-22 05:24
贵州百灵财务造假案处罚方案出炉 公司领千万罚单、董事长被禁十年、股票将"ST" 作者 胡群 贵州百灵(002424.SZ)12月19日晚间连续发布两则公告,公布了这家上市药企长达数年的财务造假案调 查结果及处理方案。一则为贵州百灵企业集团制药股份有限公司关于公司及相关当事人收到《行政处罚 事先告知书》的公告。经查,贵州百灵在2019年至2021年及2023年,通过不当核算销售费用,在2019— 2021年虚增利润,在2023年虚减利润,导致四年年报存在虚假记载。监管拟对公司处以1000万元罚款; 对时任董事长姜伟处以500万元罚款,并采取10年证券市场禁入措施;另有多名高管及独立董事被处以 50万至350万元不等的罚款。 另一则公告显示,因触及财务报告虚假记载的相关规定,贵州百灵股票自2025年12月23日起被实施其他 风险警示,股票简称将由"贵州百灵"变更为"ST百灵"。这意味着公司即将面临行政处罚、人员追责与资 本市场警示的三重后果。 根据贵州证监局下发的《行政处罚事先告知书》,贵州百灵涉嫌违法的核心事实在于财务核算未执行企 业会计准则,未以权责发生制为基础计提销售费用,导致利润数据严重失真。 2019年 ...
贵州百灵:四年财务造假公司及相关负责人被罚2560万 董事长姜伟十年市场禁入
Group 1 - The company Guizhou Bailing (002424.SZ) and 10 related individuals received an administrative penalty notice from the Guizhou Securities Regulatory Bureau for financial misconduct, including failing to adhere to the accrual basis of accounting [1][3] - From 2019 to 2021, the company understated sales expenses by 350 million, 241 million, and 64 million yuan respectively, leading to an overstatement of profits by up to 115.35% of the total reported profit for those periods; in 2023, sales expenses were overstated by 459 million yuan, with a profit understatement of 93.17% [1][3] - The company will be fined 10 million yuan and ordered to correct its financial statements; the former chairman Jiang Wei will face a 5 million yuan fine and a 10-year ban from the securities market [1][3] Group 2 - The company's stock will be suspended for one day on December 22, 2025, and will resume trading on December 23, 2025, with additional risk warnings; the stock name will change from "Guizhou Bailing" to "ST Bailing," while the stock code remains 002424, and the daily price fluctuation limit will be adjusted to 5% [2][3]
贵州百灵、福能东方、八一钢铁收到行政处罚事先告知书 投资者可索赔
Xin Lang Cai Jing· 2025-12-22 03:59
Core Viewpoint - Three companies, Guizhou Bailing, Funu Dongfang, and Bayi Steel, have received administrative penalty notices from the China Securities Regulatory Commission (CSRC) for various financial misconducts, leading to potential claims from affected investors [1][6]. Summary by Company Guizhou Bailing - Guizhou Bailing failed to comply with the accounting standards, resulting in significant misstatements in financial reports. The company underreported sales expenses and overstated profits for the years 2019, 2020, 2021, and 2023, with the following discrepancies: - 2019: Underreported sales expenses by 350.12 million, overstated profits by 350.12 million, representing 95.73% of reported profit [2][7] - 2020: Underreported sales expenses by 240.81 million, overstated profits by 240.81 million, representing 115.35% of reported profit [2][7] - 2021: Underreported sales expenses by 63.79 million, overstated profits by 63.79 million, representing 45.04% of reported profit [2][7] - 2023: Overreported sales expenses by 459.41 million, understated profits by 459.41 million, representing 93.17% of reported profit [2][7] Funu Dongfang - Funu Dongfang's subsidiary engaged in fraudulent transactions that inflated profits. The company reported: - 2020: Inflated profits by 35.80 million, which was 120.18% of the reported profit due to fictitious receivables [3][8] - 2021: Recognized a loss on inflated prepayments, reducing profits by 22.65 million, which was 6.64% of the reported profit [3][8] Bayi Steel - Bayi Steel was involved in non-operational fund transactions with its controlling shareholder, leading to undisclosed financial activities: - 2022: Received 3.68 billion and transferred 3.64 billion to the controlling shareholder [4][9] - 2023: Received 2.81 billion and transferred 2.77 billion [4][9] - 2024: Received 2.51 billion and transferred 2.53 billion [4][9] - The company failed to disclose these transactions in its annual reports for 2022, 2023, and 2024, resulting in significant omissions [4][9]. Investor Claims - Investors who suffered losses due to the misconduct of these companies may be eligible for compensation based on specific purchase and sale dates of their shares: - Guizhou Bailing: Purchases between April 30, 2020, and November 8, 2024 [5][10] - Funu Dongfang: Purchases between April 14, 2021, and December 6, 2024 [5][10] - Bayi Steel: Purchases between April 18, 2023, and November 7, 2025 [5][10]